Baylor Charles A. Sammons Cancer Center

Transcription

Cancer UPDATE
Charles A. Sammons Cancer Center at Dallas
Baylor Charles A. Sammons
Cancer Center Network: A
Brand that Stands for Quality
Cancer Care
When someone receives a diagnosis of cancer, a world of difficult choices
lies ahead. One of the first and most important decisions for the new patient
is deciding where to go to get quality care. For people living in North Texas,
an obvious answer to this question is Baylor Charles A. Sammons Cancer
Center at Dallas. For more than 35 years, Baylor Sammons Cancer Center
has been providing quality clinical care, advanced technology, and clinical
research to patients, along with comprehensive support services and
programs for patients and their families. With the opening of a new 10-story
outpatient treatment facility last year, it is now the largest outpatient cancer
center in North Texas. The center is fully integrated with Baylor T. Boone
Pickens Cancer Hospital, the region’s first dedicated cancer hospital.
Clinicians at Baylor Sammons
Cancer Center strive for
“precision medicine,” using a
coordinated, multidisciplinary
approach to create effective
treatment plans specific to
each patient. They are currently
enrolling patients in more than
100 clinical trials, including 44
phase I/II trials.
However, this obvious answer
may not be the best choice for
individual patients. For some,
(Continued on page 3)
Volume 3 • Number 1 • Fall 2012
In This Issue
2 From the Medical Director
5 Dallas Hope to Air in November
6 Baylor Regional Medical Center at Plano
8 Baylor Medical Center at Waxahachie
10 Baylor Medical Center at Garland
12 Baylor Regional Medical Center at
Grapevine
14 Baylor All Saints Medical Center at
Fort Worth
16 Baylor Medical Center at Irving
18 Clinical Trials on the Baylor Dallas Campus
20 Upcoming Oncology Meetings
21 Site-specific Tumor Conferences
22 Publications
24 GI Cancer Conference 2013
2 Baylor Sammons Cancer Center CancerUpdate
Cancer UPDATE
Volume 3 • Number 1 • Fall 2012
CancerUpdate is a publication of Baylor
Charles A. Sammons Cancer Center at Dallas,
Baylor University Medical Center at Dallas.
BaylorHealth.edu/Sammons
214.820.3535
Editor in Chief: Alan M. Miller, MD, PhD
Chief of Oncology, Baylor Health Care System
Medical Director, Baylor Charles A. Sammons
Cancer Center at Dallas
Managing Editor: Jana Pope
Writers and Assistant Editors: Lorraine Cherry, PhD, Margaret Hinshelwood, PhD, and Audrianne
Schneider, FACHE
To be removed from the mailing list, call
1.800.9BAYLOR.
Physicians are members of the medical staff at
one of Baylor Health Care System’s subsidiary,
community, or affiliated medical centers and are
neither employees nor agents of those medical
centers, Baylor University Medical Center at Dallas,
or Baylor Health Care System.
Cancer research studies on the campus of Baylor
University Medical Center at Dallas are conducted
through Baylor Research Institute, Texas Oncology,
and US Oncology. Each reviews, approves, and
conducts clinical trials independently.
Copyright © 2012, Baylor Health Care System.
All rights reserved. SAMMONS_377_2012 DH
Baylor Charles A. Sammons
214.820.3535 or 1.800.9BAYLOR
Our referral, consult, and information line
offers easy access for:
• Physician referrals
• Follow-up on patients to referring
physicians
• Medical records
• Information on clinical trials
• Specialized services
• New patient information, maps, and
lodging information
From the Medical Director
A Flower
Becomes a Bouquet
Juliet was right when she said, “What’s in a name?
That which we call a rose by any other name would
smell as sweet.” Yet when we hear the word “rose,”
we can visualize the extravagantly lovely, velvety blossom and imagine the perfumed scent. A single word
or phrase can convey sights, smells, sounds; it can
also convey a level of quality and depth of service.
We all easily recognize certain automobile brands,
hotel names, and health care providers that instill a
level of comfort and confidence when we hear them.
Alan M. Miller, MD, PhD
chief of oncology,
Baylor Health Care
System and medical
director, Baylor
Charles A. Sammons
The name Baylor Charles A. Sammons Cancer Center
represents a level of care, excellence, and confidence
that assures patients they will receive evidence-based,
compassionate treatment with access to advanced clinical research
and innovation. By achieving accreditation from the American College of
Surgeons’ Commission on Cancer and participating in clinical research,
education, and quality initiatives, other facilities within Baylor Health Care
System have earned the distinction of being designated a Baylor Charles A.
Sammons Cancer Center at ….
This issue of CancerUpdate highlights some of the activities at the
member centers. Joining Baylor Charles A. Sammons Cancer Center at
Dallas are Baylor Charles A. Sammons Cancer Centers at Fort Worth,
Garland, Grapevine, Irving, Plano, and Waxahachie. The cancer programs
at the two newest hospitals in the health care system—Baylor Medical
Center at Carrollton and Baylor Medical Center at McKinney—are well
on their way to achieving accreditation and designation. In this issue, you
will see a sampling of the patient care programs and research available
throughout our system.
Baylor Sammons Cancer Center CancerUpdate 3
(Continued from page 1)
the logistic problems of a long commute in big-city traffic
can multiply quickly when they are not feeling well and when
treatment schedules may mean three or more visits each
week. The comfort and convenience of staying in their own
community for treatment may weigh heavily in their decision.
But does opting for convenience mean reduced access to
the newest equipment, research, or clinical trials that may
offer more effective treatment options? How can patients
be assured that they are not sacrificing quality of care for
convenience?
The decision about where to go for cancer care in North
Texas has now become easier with the launching of the
Baylor Charles A. Sammons Cancer Center network. Baylor
medical centers throughout North Texas can achieve the
distinction of using the Baylor Sammons Cancer Center
name for their oncology programs by meeting or exceeding
the stringent criteria established by Baylor Health Care
System (BHCS). All patients within the service area of each
Baylor facility can then have confidence that the services
provided at that facility meet the same criteria, regardless
of the location of services.
How Does a Baylor Facility Qualify
to Carry the Baylor Sammons
Cancer Center Brand?
Each Baylor institution desiring to join the network must
submit a request to BHCS oncology leadership showing
its readiness:
1. They must have received accreditation by the Commission
on Cancer (CoC) of the American College of Surgeons as
an approved cancer program. Accreditation by the CoC
indicates that a cancer program provides high-quality care
as measured against national standards and continuously
strives to address each patient’s needs while improving
outcomes.
2. They must meet specific requirements demonstrating
active participation by their Cancer Committee physician
leader, administrative director/representative, and oncology
nursing leader in BHCS oncology strategic initiatives.
active participation in BHCS oncology safety and health
care improvement projects.
active participation in BHCS oncology educational efforts
in nursing, medicine, or other ancillary education related
to oncology.
5. They must demonstrate participation in research initiatives,
either within the facility or by supporting other Baylor
facilities and their oncology research by making clinical
trials available to patients, regardless of the location of
the trials.
The request is reviewed by the BHCS oncology leadership
team to assess whether the facility has met the membership
criteria and to ensure the facility’s ongoing commitment.
If it is determined that all criteria have been met, the Baylor
facility then has the distinction of using the Baylor Charles
A. Sammons Cancer Center name.
To date, six Baylor institutions, along with Baylor Charles A.
Sammons Cancer Center at Dallas, have been recognized
with this distinction:
1. Baylor All Saints Medical Center at Fort Worth
2. Baylor Medical Center at Garland
3. Baylor Medical Center at Irving
4. Baylor Medical Center at Waxahachie
5. Baylor Regional Medical Center at Grapevine
6. Baylor Regional Medical Center at Plano
The two newest Baylor institutions, Baylor Medical Center
at Carrolton and Baylor Medical Center at McKinney, are
currently working toward fulfillment of the membership criteria.
How Does Accessing the Baylor
Sammons Cancer Center Network
Benefit Patients?
Patients will be the major beneficiaries of the Baylor Sammons
Cancer Center network. When initially deciding upon a
treatment center, they will have the assurance that any
Baylor Charles A. Sammons Cancer Center Network
“The Baylor Charles A. Sammons Cancer Center name represents a high level of care and excellence.
The growth of our network, adding the strengths of our cancer programs in Fort Worth, Garland,
Grapevine, Irving, Plano, and Waxahachie, further enhances that name by bringing the assets of those programs together with Baylor Charles A. Sammons Cancer Center at Dallas.”
Alan M. Miller, MD, PhD
institution carrying the Baylor Sammons brand will offer
quality cancer care. By receiving care at a Baylor Charles A.
Sammons Cancer Center, patients can be treated close to
home for most of their cancer care needs.
How Does Participation in the Baylor
Sammons Cancer Center Network
Benefit Member Institutions?
Patients will be able to draw upon the strength of the entire
network in terms of access to nationally recognized experts
in the treatment of various types of cancer and the availability
of specialized equipment. Patients with complex treatment
issues will have many heads discussing their care, and when
necessary, can benefit from a seamless transition to some of
the unique services available at the Baylor Sammons Dallas
campus. This includes the Blood and Marrow Transplant Unit,
newly relocated at Baylor T. Boone Pickens Cancer Hospital,
as well as earliest access to new agents being tested in Phase
I/II trials at the Innovative Clinical Trials Center. Nurse navigators
will work with the patients’ clinicians to identify specialized
services and clinical trials that can provide the best treatment
options for selected patients, regardless of the site. A newly
hired genetic counselor from Baylor Sammons Cancer Center’s
Hereditary Cancer Risk Program will travel to other institutions
within the network to provide counseling services for patients
with a full range of cancers who might benefit from genetic
testing based on personal or family history.
Becoming a member of the Baylor Sammons Cancer Center
network requires demonstrating quality in the care of cancer
patients. All of our member institutions are doing that—and
documenting that they are doing it. There is more dialogue
among physicians throughout the metroplex, allowing us
to educate each other as physicians. Rather than having to
“reinvent the wheel” at each site to develop new treatment
options or patient outreach programs, physician leaders from
each institution can come to the quarterly Baylor Health Care
System Oncology Council to share ideas and best practices
with colleagues at their sister facilities. A program that has
been developed and perfected at one center can be used as
a model at other sites. Cooperation among cancer centers
can bring the strength of numbers to bear on conducting new
clinical trials that make innovative treatment options available
to patients.
In the rest of this issue of CancerUpdate, we
highlight the member institutions of the Baylor
Sammons Cancer Center network, describing the
special achievements and programs that make
each cancer care center exceptional.
Dallas Hope to Air in November
The premiere of Dallas Hope, Baylor Health Care System’s unprecedented documentary series highlighting the hope that
follows a cancer diagnosis, will air on November 8, 15, and 17 at 6:30 p.m on WFAA/Channel 8. The series follows the lives
of three cancer patients undergoing treatment at Baylor Charles A. Sammons Cancer Center at Baylor University Medical
Center at Dallas, recently named the #1 hospital in Dallas/Fort Worth according to U.S. News & World Report. Their heart-felt
journeys and real life battles with cancer invoke awe in viewers who witness their everyday acts of courage, faith, and hope.
Those in the Dallas/Fort Worth metroplex can watch the program live on WFAA/Channel 8. Full episodes will also be
available for all to view at DallasHope.com shortly after they air.
Baylor Regional Medical Center at Plano
About Baylor Plano
Baylor Regional Medical Center at Plano is a 160-bed acute
care hospital located approximately 18 miles northeast of
Dallas, serving North Texas since December 2004. According
to Mark Engleman, MD, medical director of oncology at
Baylor Plano: “When I got here, we did not have any template
for how to develop a cancer care program. It was a blank
slate, with no cancer registry and no tumor conferences.
Working with a lot of support from Baylor administration, our
goal was to create an academic oncology atmosphere in a
community hospital setting.”
Significant progress has been made toward achieving this
goal in the ensuing 8 years. The center now has a 32-bed
dedicated inpatient oncology unit and 10,000 square feet of
outpatient space (including 15 infusion chairs) made available
through a collaboration with Texas Oncology. Baylor Plano
sees more than 2,000 patients each year, including more
than 750 newly diagnosed patients. Six site-specific cancer
conferences are now held each month: two for breast cancer
and one each for lung, genitourinary/prostate, gastrointestinal,
and combined head and neck/melanoma. Accreditation as
an approved cancer program by the Commission on Cancer
was achieved in 2009, with recognition of distinction in all
eight categories.
Baylor Plano continues to grow quickly, appropriate for its
location in the fastest-growing county in Texas and one of
the 10 fastest-growing counties in the United States. It is
doubling its capacity in radiation oncology, with the acquisition of a new linear accelerator. It actively participates in
clinical trials through collaborations with Mary Crowley Cancer
Research Center and US Oncology. Through a collaboration
with US Oncology, Baylor Plano has also become an approved
site for Radiation Therapy Oncology Group (RTOG) trials.
Special Achievements in Cancer Care
at Baylor Plano
Breast Cancer
Baylor Plano is especially proud of its accreditation by the
National Accreditation Program for Breast Centers (NAPBC).
Joseph Brown, director of oncology at Baylor Plano, commented: “This is an exciting accomplishment for us, because
we are the first community hospital in the Baylor system to
have this distinction.” To be accredited, a cancer center must
meet or exceed breast cancer treatment standards in leadership, clinical management, community outreach, professional
education, and quality improvement. In keeping with these
standards, Baylor Plano offers a comprehensive breast cancer
treatment program, including risk assessment, diagnosis,
surgery, radiation oncology, and medical oncology. According
to Lynn Canavan, MD, director of breast surgical oncology at
Baylor Plano, “Baylor Plano’s position in the Baylor Sammons
Cancer Center network will show women that they can get
quality care really close to home, avoiding the stress of traveling
all over the metroplex.”
Baylor Plano has also developed a successful breast cancer
risk assessment program. Women at high risk for breast cancer are identified through questionnaires that are distributed
when they come for routine screening mammograms or by
referral from their personal physician. They are invited to
come to an educational event where experts discuss lifestyle
changes that can reduce risk and provide a demonstration
of how to perform a breast self-examination. In addition,
members of the oncology team are providing this educational
program on site to employees of local schools and businesses. Participants may be recommended for a long-term
surveillance program, where they will be counseled on
therapies to decrease risk (such as anastrozole or tamoxifen),
the pros and cons of prophylactic mastectomies, and strategies for detecting cancer earlier. While this risk assessment
program is currently in place for breast cancer, plans are to
eventually extend it to other cancers.
For patients newly diagnosed with breast cancer and their
family members, the days between diagnosis and the onset
of treatment can be overwhelmingly stressful. To help them
deal with this stress, Baylor Plano has developed a preoperative orientation program designed to help familiarize them
with the strange surroundings and unfamiliar situations. The
patient and family members come to the campus before
surgery to meet with a nurse navigator, hear about support
programs at the hospital and in the community, and take a
tour of the hospital. They have the opportunity to ask any
questions they might have about the surgical procedure itself.
They have their arms measured by a physical therapist to aid
in tracking early stages of lymphedema, when this condition
may still be largely preventable. They meet with breast cancer
survivors who work as Reach to Recovery volunteers and
are introduced to their preop nurse, who describes what they
need to do on the morning of surgery. This program, which
has been very well received by patients and their family members, has been expanded to include patients with head and
neck cancer, who also receive specialized education
from a nutritionist.
C2H: A Stress Management and Coping Intervention
for Patients with Cancer
C2H stands for “Cancer to Health,” the first evidence-based
biobehavioral intervention designed for people recently diagnosed with cancer. Developed at The Ohio State University
by Barbara L. Anderson, PhD, the C2H program is a set of
behavioral and psychological interventions aimed at improv-
ing immune system functioning, preventing cancer recurrence,
improving quality of life, and improving psychological distress
associated with a cancer diagnosis. Patients meet weekly for
16 weeks, where they learn and practice specific behavioral
and cognitive skills which help them cope with the stress of
cancer. Based on up to 11 years of follow-up data collected
by Dr. Anderson and colleagues, breast cancer patients who
participated in the C2H program at OSU experienced a 77%
reduction in anxiety after 4 months, a 295% improvement
in physical functioning at 1-year follow-up, and an amazing
55% reduction in risk of recurrence. The program has been
launched at Baylor Plano by Jamile Ashmore, PhD, director
of the Behavioral Health Center at Baylor Plano, with the
assistance of Lindsey DeBor, MA, PhD candidate in clinical
psychology. Dr. Ashmore commented: “Behavioral and psychological factors often remain untreated in cancer patients,
despite the fact that they can have an enormous effect on
overall health and outcomes. I am excited that we will be
able to offer the C2H program as a service to our patients.”
Baylor Medical Center at Waxahachie
About Baylor Waxahachie
Waxahachie is located in Ellis County, approximately 30
miles south of Dallas. With its broad industrial-based economy, Waxahachie is a fast growing area, and Baylor Medical
Center at Waxahachie is growing to keep up with the
increasing population.
Baylor Waxahachie provides technologically advanced
medical care for residents of Ellis and southern Dallas counties. This includes Waxahachie, in addition to Midlothian, Red
Oak, Ennis, and other surrounding communities. Originally
opened as the Waxahachie Sanitarium at the beginning of
World War I, the hospital joined Baylor Health Care System
in 1983. Baylor Waxahachie prides itself on using innovative
technology to bring urban medical resources to its suburban
community and is known throughout Baylor Health Care
System for its implementation of the telemedicine robot to
provide specialty physician consults.
The quality of care available at Baylor Waxahachie has been
demonstrated through recent accolades, including:
• The 2012 Texas Award for Performance Excellence given
by the Quality Texas Foundation. This award recognizes
Texas organizations that have achieved performance
excellence and applied outstanding quality principles in
their day-to-day operations.
• A Thomson Reuters 100 Top Hospital® award recipient in
both 2011 and 2012.
• Designation as a Pathway to Excellence® facility by the
American Nurses Credentialing Center, which identifies a
work environment where nurses can flourish and are
empowered to provide outstanding care to patients.
“The timeline is so aggressive because Baylor Health Care System realizes the need and realizes that
we don’t really have a choice… right now, we offer a lot; we want to offer everything.”
Valerie Gorman, MD
at Baylor Waxahachie
Bringing Advanced Cancer Care to the
Community Hospital Setting
In the field of cancer care, Baylor Waxahachie has already
achieved a high standard of quality, with exciting plans for the
future. It has received accreditation as an approved cancer
program by the Commission on Cancer, with special commendation in all eight categories possible. Imaging facilities
at Baylor Waxahachie have received accreditation by the
American College of Radiology for magnetic resonance imaging, ultrasound, computed tomography, mammography, and
stereotactic imaging, and the Gerard Noteboom Laboratory
is accredited by the Commission on Laboratory Accreditation
of the College of American Pathologists.
In 2011, clinicians at Baylor Waxahachie treated 295 cancer
patients, of whom 188 were new patients. The most frequent
types of cancer seen were breast, digestive system, respiratory system, and urinary system. The total number of cases
seen represented a 27% increase over the previous year.
Baylor Waxahachie has just begun a nurse navigator program,
with its first navigator now on board. She assists patients
with record collection, appointment scheduling, and followup, and will be present (when requested) on procedure days.
The navigator will also help in identifying clinical trials for
patients when appropriate.
A Growing Medical Center to Support
a Growing Community
For all of its excellence in providing quality care, Baylor
Waxahachie reached a point several years ago where it was
running out of room to expand services. The existing medical
center is surrounded by a park and a flood plain, leaving no
room for growth.
Recognizing the need, Baylor Health Care System purchased
50 acres at the intersection of I-35 and Highway 287, about 4
14
0
2
R
E
VEMB
O
N
G
COMIN
miles north of the existing campus. An entirely new campus
will be built on this site, including a new hospital and an
outpatient cancer center. Baylor Waxahachie’s vision for
the new outpatient cancer center is a multidisciplinary clinic
approach that will bring together oncologists, surgeons,
radiologists, educators, dietitians, rehabilitation therapists,
and research coordinators. Patients from the surrounding
area will be able to receive complete care close to home,
starting with diagnosis and including biopsy, imaging, surgery,
adjuvant therapy, and radiotherapy. Laura Mobley, director of
clinical informatics/oncology at Baylor Waxahachie, stated:
“We are excited that we will be able to offer comprehensive
cancer services right here in Waxahachie. Our staff is working
very hard to bring quality cancer care to our community, as
evidenced by our recent certification by the Commission on
Cancer, in which Baylor Waxahachie received eight of eight
commendations.”
Completion of the new facility is targeted for November 2014.
Asked about this aggressive timeline, Valerie Gorman, MD,
chief of staff at Baylor Waxahachie, said: “The timeline is so
aggressive because Baylor Health Care System realizes the
need and realizes that we don’t really have a choice. Right
now, we offer a lot; we want to offer everything.”
Baylor Medical Center at Garland
at Baylor Garland
About Baylor Garland
Garland is located about 12 miles northeast of Dallas. It is a
medium-sized city, the 12th largest in the state of Texas, with
a population of a little under a quarter of a million. In 2008,
Money magazine ranked it as one of the best places to live in
the United States.
Baylor Medical Center at Garland is a 240-bed hospital serving the residents of Garland and the neighboring communities
of Wylie, Rowlett, Sachse, Mesquite, and Murphy. Started in
1966 as Memorial Hospital of Garland, it was purchased by
Baylor in early 1992.
Baylor Garland provides quality, comprehensive care
for patients with all types of cancer, as documented by its
recent accreditation from the Commission on Cancer of the
American College of Surgeons. It has also received a 3-year/
full accreditation designation by the National Accreditation
Program for Breast Centers (NAPBC), reflecting the quality
of care available at the Baylor Breast Center at Baylor
Garland. The Breast Center has a care team that includes
certified mammography technologists, radiologists, and
breast surgeons on the medical staff of Baylor Garland. They
provide screening and diagnostic digital mammography services, bone density testing, stereotactic breast biopsies, and
ultrasound-guided procedures, among other services.
The Therapeutic Touch Time team (left to right): Tammy
Hopner, MSW, Jane Mwangi, RN (seated at computer),
Zhiyong Li, MD, oncologist, and Prabh Batra, BSN, RN.
Clinicians, nurses, and administrators at Baylor Garland
understand that providing the best care for cancer involves
much more than advanced medical treatments. Newly
diagnosed patients are frequently overcome with emotion
and stress, to the point that assimilating new information
and making important, life-altering decisions is extremely
difficult. Patients at the other end of the treatment spectrum,
approaching the end of life, need other types of support to
ease the end of the journey for themselves and their family
members. Baylor Garland now has programs to address
these critical needs.
Therapeutic Touch Time: A Team Approach
for Helping Patients and Families Learn
About Cancer
Therapeutic Touch Time is a team approach to help patients
and families ask questions and gain understanding about
cancer. It was developed by oncology nurse Prabh Batra,
BSN, RN, supervisor of the Medical/Surgical Oncology Unit,
in response to needs she encountered in more than 20 years
of working with oncology patients. Evidence-based practice
had shown that the most important needs identified by patients
were related to information and communication about their
disease process and adequacy of pain management. Batra
and her team developed Therapeutic Touch Time as a method
for the patient and family to meet and seek information from
the entire cancer care team.
When newly diagnosed patients are identified by the nursing
staff, Batra visits with them to discuss the program and set
up a time to meet. She gives them a notebook and a pen
and urges them to write down any questions they might have
about any aspect of their cancer or treatment. The Therapeutic
Touch Time team includes an oncologist, nurse, social worker,
and chaplain. Having all of these members present at once
helps eliminate any contradictory or confusing messaging
unintentionally given by individual practitioners. The team
meets with the patient and family to discuss the diagnosis,
treatment options, what to expect as treatment progresses,
and the resources (physical, spiritual, financial) available. By
having the opportunity to talk with all of these team members,
the patient and family have a better understanding about the
roles of the various disciplines. For example, people often do
not understand the role of the social worker, although many
may need the social worker’s expertise to deal with financial
issues or to draw together available resources.
Batra is assisted in conducting this program by social worker
Tammy Hopner, MSW, and oncology nurse Jane Mwangi, RN,
who serves as team leader for the program. To date, patients
have responded very favorably to the Therapeutic Touch Time
intervention, indicating via questionnaire that they have a better
understanding of their disease and the resources available
to them and are more satisfied overall with their treatment at
Baylor Garland.
Batra herself is pleased with the outcomes from this team
approach to educating patients and their families. “With some
of my patients,” she said, “it was heartbreaking to see how
frightened they were, largely because they didn’t understand
what was going on. I wanted to do something positive to
make it easier for them to deal with the whole process. The
reason that I called it Therapeutic Touch Time was because
they really touch my heart.”
Palliative Care and Hospice at Baylor Garland
Patients with advanced cancer frequently suffer from a variety
of painful and unpleasant symptoms, either from their disease
or as side effects from the treatment they receive. The suffering is not only physical, but may also be psychological, spiritual, or social. Palliative care aims to relieve this suffering and
improve quality of life for patients with advanced life-limiting
illness and their families. Although frequently confused with
hospice care, palliative care differs in that it may be simultaneously offered with all other appropriate medical treatments,
or it may replace treatments that no longer benefit the patient.
Palliative care offers a bridge to hospice treatment.
Baylor Garland has a very active palliative care/hospice program and is currently seeking accreditation for the program
from the Joint Commission for Disease Specific Certification
in Palliative Care. The palliative care team, which meets
weekly, includes four physicians, with one already boardcertified in palliative care and two more who are preparing to
sit for those boards. The team also includes input from social
work, chaplaincy, pharmacy, speech therapy, occupational
therapy, and nutrition.
A patient may be considered for palliative care on the recommendation of a physician or nurse, or the patient or a family
member may request it. An innovative program initiated at
Baylor Garland involves the use of evidence-based assessment tools in the emergency room to determine if a patient
should be referred directly to palliative care. According to
Janice Walker, MBA-HCM, BSN, RN, chief nursing officer/
chief operating officer at Baylor Garland: “Previously, an
attending physician in the ER had to recognize the need and
call for a palliative care assessment. With the use of evidencebased assessment tools, the palliative care referral can
happen very quickly.” The assessment tool incorporates age,
chronic disease, frailty scale, and pain assessment, among
other parameters, in determining the appropriateness of
palliative care. The use of these evidence-based tools to refer
patients for palliative care is part of a hard-wiring of the process that is necessary to achieve accreditation as a palliative
care center. Similarly, a well-defined program must be in place
for offering hospice care to patients whose passing appears
to be imminent (5–6 days).
Part of the process of running a palliative care program involves
educating patients about what is involved. Many patients confuse palliative care with hospice and assume that their doctors
have given up hope and will no longer treat their disease once
palliative care is initiated. Most are surprised to learn that, not
only is this not the case, but frequently patients on palliative
care have more favorable outcomes, including longer survival
times, than patients who remain on standard therapy alone.
Eventually, however, the palliative care team will need to help
people make difficult decisions. Jeffrey Kopita, MD, a pulmonologist on the medical staff at Baylor Garland and member of
the palliative care team, commented: “The initial goal of oncology
care is to cure the patient or place the patient in clinical remission.
If this is not possible, palliative care is indicated. Palliative care
is total care of the patient whose disease is not responsive to
curative therapy. It involves a multidisciplinary approach to the
relief of symptoms in order to give the patient the best quality
of life possible, despite their disease.”
Baylor Regional Medical Center at Grapevine
About Baylor Grapevine
The city of Grapevine was originally named for the wild grapes
that were once prevalent in the area. In a 2007 CNNMoney.com
survey, it was named as one of America’s best places to live.
One of the advantages of living in this Dallas suburb relates to
the availability of quality medical care, offered locally at Baylor
Regional Medical Center at Grapevine.
Baylor Grapevine is a 256-bed full-service hospital focused
on being trusted as one of the best places to give and receive
safe, quality, compassionate health care. Baylor Grapevine’s
advanced oncology care services have been recognized with
three national accreditations. The American College of Surgeons
has provided recognition with a 3-year accreditation as an
approved cancer care program from its Commission on Cancer.
Recognition from the National Accreditation Program for
Breast Centers (NAPBC), also administered by the American
College of Surgeons, reflects the high quality of care offered
at the Comprehensive Breast Center at Baylor Grapevine.
The American College of Radiology has designated Baylor
Grapevine as a Breast Imaging Center of Excellence (BICOE),
based on accreditations in mammography, stereotactic breast
biopsy, and breast ultrasound (including ultrasound-guided
breast biopsy).
These accreditations provide an assurance to cancer patients
who come to Baylor Grapevine that they will receive comprehensive, multidisciplinary care, including the opportunity
to participate in ongoing clinical trials with new treatment
options, and that they will receive this quality care close
to home. According to Nikoma Wolf, director of oncology
services, 612 patients with cancer were treated at Baylor
Grapevine last year.
Nurses on the unit are specially trained in caring for people
with cancer and have received additional education in the
biology of cancer and chemotherapy. Patients also have
access to other hospital resources during their stay, including
pastoral care, counseling, social work, nutritional services,
and a dedicated family resource center.
The Inpatient Oncology unit is working to have 100% of its
nurses certified as oncology nurses. Requirements for certification include a minimum of 1,000 hours of adult oncology
nursing practice within the 30 months prior to application,
completion of approved nursing education in oncology
nursing, and satisfactory results on a written examination.
The Comprehensive Breast Center
at Baylor Grapevine
Baylor Grapevine’s Comprehensive Breast Center provides
women with access to comprehensive breast care close to
home, meaning less waiting for a diagnosis, less disconnect
between different specialists, and less travel time between
appointments.
The Comprehensive Breast Center also offers:
• Full-service imaging, including digital mammography and
high-resolution diagnostic ultrasound. (Breast MRIs are
available at two nearby Baylor facilities.)
• A network of surgical, medical, and radiation oncologists
on the Baylor Grapevine medical staff who can help
develop an individual treatment plan.
• Assessment and counseling for women at high risk for
breast cancer.
at Baylor Grapevine
• Meeting space where Look Good…Feel Better®, an
educational class for women undergoing breast cancer
treatment, and other support groups can gather.
Dedicated Oncology Unit
Plans are being made to introduce breast tomosynthesis as
an imaging option. “We want to investigate any new technology
that may help us find breast tumors earlier,” said Scott Woomer,
MD, medical director of Baylor Grapevine’s Comprehensive
Breast Center. Dr. Woomer anticipates that this technology
may be especially useful in screening younger women with
Located in the hospital on the fifth floor of the Carter building,
the inpatient unit is dedicated to the quality care of adult cancer patients and their families when hospitalization is required.
The Oncology Unit employs a unique nursing model to meet
the physical, psychological and emotional needs of patients.
dense breast tissue or as a diagnostic tool to investigate
suspicious lesions detected with regular screening
mammography.
A major component of cancer treatment at Baylor Grapevine’s
Breast Center is that it is not just about diagnosing and treating
cancer. “It is about compassion and caring, and we do a
good job of that,” said Dr. Woomer. “A huge factor in our
program is working to ensure that we help meet the psychological needs of patients and their families.”
Other Accomplishments in Oncology Care
• A General Tumor Board and a Cancer Committee that was
organized at the same time have been very successful in
maintaining high standards of multidisciplinary care at
Baylor Grapevine. Founded in 2008, the Tumor Board
meets monthly, with multiple physicians and nurses in
attendance who work through cases in a multidisciplinary
fashion. A site-specific tumor board and committee are
now in place for breast cancer, with plans to expand the
program to include site-specific meetings for colorectal
and thoracic tumors.
• A full-time nurse navigator has been in place for three
years at Baylor Grapevine, working primarily with breast
cancer patients to help arrange appointments, make sure
all questions are answered, and help to arrange access
to clinical trials and support groups. Plans for the future
include expanding this program to other cancer sites.
• Diagnostic imaging services now available for patients at
Baylor Grapevine include a 64-slice CT scanner for virtual
colonoscopy, in addition to a small bowel camera in the
endoscopy lab and standard colonoscopy services;
advanced lung analysis; MRI; ultrasound; nuclear medicine;
and PET/CT (available through a collaboration with Texas
Oncology).
• A significant investment has been made in expanding
surgical services. More complex surgeries are being done,
and the da Vinci® robotic surgery system is being used for
selected gynecologic and prostate cancers.
Vikas Aurora, MD, hematologist and medical oncologist on
the medical staff as well as the chairman of the Cancer
Committee at Baylor Grapevine, is excited about the growth
of the program: “We are working to be at the forefront of
community cancer care by integrating physician and nurse
enthusiasm with administrative support,” he said. “It takes
time and resources to fuel growth but we have it here, with
the strong support of Baylor Health Care System.”
Baylor All Saints Medical Center at Fort Worth
About Baylor Fort Worth
Fort Worth, long considered the “gateway to the West,” was
once the last vestige of civilization enjoyed by cattle herders
before setting off on the Chisholm Trail for the rail yards of
Kansas. Rapid growth over the last decade has resulted in an
estimated 2011 population of approximately 760,000, making
Fort Worth the second largest city in North Texas.
The size and rapid growth of Fort Worth make it an appropriate
site for Baylor All Saints Medical Center at Fort Worth, the
second largest hospital in Baylor Health Care System. With
575 beds and a wide variety of medical services, Baylor Fort
Worth had nearly 21,000 inpatient admissions, 35,000 emergency department visits, and 52,000 outpatient visits last year.
Baylor Fort Worth is nationally accredited by the Commission
on Cancer as a “Community Hospital Comprehensive Care
Program,” offering a full range of oncology services with a
multidisciplinary approach. The program has 26 private
inpatient rooms, staffed by experienced oncology nurses.
A 13-unit outpatient infusion area is located near the inpatient
center. Radiotherapy is offered through a collaboration with
Texas Oncology in a facility adjacent to the hospital. More
than 1,200 cancer patients are seen at Baylor Fort Worth
each year.
Baylor Fort Worth has special strength in the areas of breast
cancer, gynecologic cancer, and head and neck cancer,
which are supported by regularly scheduled site-specific
cancer conference meetings, in which ongoing and complex
cases are reviewed. Attendees provide multidisciplinary input
to assist in designing optimal treatment plans for the patients.
An additional cancer conference addressing other cancer
sites is also held on a regular basis.
at Baylor Fort Worth
Research
In collaboration with clinicians from Texas Oncology and the
Center for Cancer and Blood Disorders, Baylor Fort Worth
“Our focus is to provide a full range of oncology services through a multidisciplinary approach to
patient care. . . . [These services] include prevention and early diagnosis, pretreatment evaluation,
staging, treatment, rehabilitation, surveillance for recurrent disease, support services, as well as
Kathleen L. Shide, MD
end-of-life care.”
maintains a very active clinical research program. Fifteen
studies are currently recruiting patients, with an additional
three pending institutional review board approval. Open studies are principally phase II and III studies, strongly focused in
the areas of breast, head and neck, and gynecologic cancer.
Additional studies are available at collaborating institutions,
including Baylor University Medical Center at Dallas and
Baylor Medical Center at Irving.
Infrastructure is in place at Baylor Fort Worth to facilitate the
recruitment of patients into research studies. Baylor Research
Institute maintains a satellite clinical trials office at Baylor Fort
Worth that serves as a comprehensive resource for initiating
and conducting clinical trials for physicians and other investigators on the medical staff. The clinical trials office staff
includes the medical director, director of clinical research,
research manager, research nurses, clinical research coordinators, and administrative staff. Among their other activities,
they produce fliers containing an explanation of clinical trials,
information about some of the specific studies that are currently recruiting patients, and directions on where to go for
more information; these fliers are distributed to patients, are
posted at the Joan Katz Breast Center and other locations,
and are provided to the nurse navigators for reference.
Research nurses carefully consider every case to determine if
a patient may be eligible for a research protocol. They review
the patient’s records with a physician to make a decision
about whether the patient qualifies. If the answer is yes and
the patient agrees to participate, the nurses enroll the patient
in the study and follow up during the course of the study to
ensure that all treatments, tests, and examinations are completed in a timely way.
David Klein, MD, interim president of Baylor Fort Worth,
believes that clinical studies that bring research to the
patient’s bedside not only provide increased understanding
of the disease, but potentially offer the patient the best
available new therapy. “Patients typically are interested in
participatingin clinical trials,” he commented. “Baylor Fort
Worth offers them the opportunity to stay close to home.”
Other Accomplishments in Oncology Care
• The Joan Katz Breast Center at Baylor Fort Worth offers
comprehensive, compassionate cancer care at one location for men and women diagnosed with breast and other
cancers. A large dedicated space includes consultation
rooms, a learning room, a video conference room, physician examination rooms, and an appearance center.
A counselor is available twice a week to provide a full
genetic evaluation of high-risk patients.
• A unique service offered at Baylor Fort Worth is the
Frances and Frank Turrella Lymphedema Center. This
center is staffed by licensed physical therapists certified
in complete decongestive therapy by the Lymphology
Association of North America.
• Baylor Fort Worth provides comprehensive evaluation,
diagnosis, and treatment services for patients with skull
base disease at the Skull Base Center.
• The Head and Neck Cancer Program offers technologically
advanced care for patients with cancers of the head and
neck.
Kathleen L. Shide, MD, a radiation oncologist on the medical
staff of Baylor Fort Worth and chair of the Cancer Committee,
emphasized that the quality of care available at this institution
is a direct function of the skill of the physicians on the medical
staff and their ability to provide coordinated, compassionate
care. This care involves the direct treatment of the disease,
but also involves much more. She commented: “Our focus
is to provide a full range of oncology services through a multidisciplinary approach to patient care. . . . [These services]
include prevention and early diagnosis, pretreatment evaluation,
staging, treatment, rehabilitation, surveillance for recurrent
disease, support services, as well as end-of-life care.”
Baylor Medical Center at Irving
About Baylor Irving
The city of Irving, located 16 miles west of Dallas, has a population of 216,290. It was founded in 1903, reportedly named
after Washington Irving, a favorite author of the wife of one of
the founders. Baylor Medical Center at Irving was opened in
1964 as Irving Community Hospital. It now has 288 beds and
is the premier comprehensive medical center serving Irving,
Las Colinas, and the surrounding communities.
With 156 cancer-related specialists on the medical staff, Baylor
Irving provides comprehensive cancer care for more than 460
newly diagnosed patients per year, in addition to more than
200 referrals. The hospital contains a dedicated Oncology Unit,
staffed with nurses who have all been certified for the administration of chemotherapy and are experienced in the care of
patients receiving radiotherapy.
Every case is presented prospectively at multidisciplinary
tumor boards, where a team approach is used to chart the
best course of treatment. Site-specific tumor boards are held
for thoracic tumors and breast tumors, with additional boards
dedicated to medical oncology and general oncology. Future
plans call for incorporating recommendations from the tumor
board as part of the patients’ medical records.
An oncology nurse navigator is on the staff at Baylor Irving,
serving as educator and advocate, care coordinator, and
system navigator for those diagnosed with cancer. At present,
the navigator assists patients with all diagnoses, but a breast
cancer–specific navigator will be hired during the upcoming
year. An oncology research nurse contacts patients who may
be eligible for clinical trials (Irving is an official site for several
breast cancer trials) and assists them in the screening process,
as well as following up on appointments for treatment and
assessment for those patients who join trials.
The quality of the cancer care program at Baylor Irving has
been recognized by accreditations from the Commission
on Cancer (with 8 of 8 possible commendations) and the
National Accreditation Program for Breast Centers (NAPBC).
In addition, Baylor Irving has received a 3-year accreditation
with commendation from the American College of Radiology.
Brenda Blain, DNP, RN-BC, FACHE, chief nursing officer/
chief operating officer at Baylor Irving, is excited about the
great strides being made in the treatment of cancer patients
at Irving: “As oncology services become more sophisticated,
Baylor Irving is committed to being a step ahead, offering
more advanced, innovative procedures with one main focus—
improving patient outcomes.”
at Baylor Irving
Radiation therapy has been used in the treatment of most
types of solid tumors for more than 100 years. Depending
on the type and location of the tumor, radiation therapy may
be curative when used alone as primary therapy or may be
used in conjunction with surgery, chemotherapy, or hormonal
therapy. Baylor Irving has eight radiation oncologists on the
medical staff, and these specialists have the experience and
tools to determine which form of radiation therapy is right
for each individual patient.
Baylor Irving offers different kinds of technologically advanced
radiation therapies, including image-modulated radiation therapy, image-guided radiation therapy, thyroid ablation therapy,
and high-dose remote afterloader brachytherapy. For early
stage breast cancer, catheter-based 5-day treatments are
offered to those who do not want conventional radiotherapy
and who meet the stringent requirements for eligibility.
In May of 2012, Baylor Irving acquired new equipment necessary to provide stereotactic radiation therapy with 4-D
gating capability. Stereotactic radiation therapy is a precise
form of radiation therapy that combines the principles of 3-D
target localization with multiple intersecting radiation beams
to precisely treat tumors in difficult or hard-to-reach areas.
Because of its precision, surrounding normal tissue is spared,
and larger doses per fraction can be used. However, organs
in the chest and upper abdomen (lung, liver, breast) can move
as much as 2 inches during normal respiration, reducing the
accuracy of the treatment. With 4-D gating capability, which
adds the dimension of time, the range of respiratory movement is measured using a multislice, 4-D computed tomography (CT) scanner. These measurements are used to optimize
treatment by continuously turning the radiation beam on and
off to synchronize delivery of radiation to the appropriate
point in the respiratory cycle.
The figure below shows the results seen in the first patient
treated with stereotactic radiation therapy at Baylor Irving.
The patient was a 71-year-old man with a 7.0 cm T2bN0M0
adenocarcinoma in the lingula of the left lung apparent on CT
scan. He was determined to be at high risk for surgery and
selected stereotactic radiation therapy for treatment after
consultation with a radiation oncologist. The patient was
treated in five fractions to a total dose of 55 Gy. A follow-up
Before:
CT scans taken
before and after
treatment with
stereotactic
radiation therapy.
Before: CT scan
reveals a 1.5 cm
mass in the lingula
of the left lung
(arrow).
After:
CT scan shows
reduction in size
of the original
neoplasm (arrow).
CT was done after the completion of treatment. While chronic
pulmonary changes were apparent, there were no new suspicious lesions. The left lingula neoplasm, although still present,
was decreased in size compared to the pretreatment CT scan
taken 4 months earlier.
From the medical and surgical oncologists to the radiation
specialists to the dietitians, the entire staff at Baylor Irving
remains focused on taking care of patients and helping them
on their path to healing. Edward Clifford, MD, clinical director
of oncology services, believes that the launch of the new
Baylor Sammons Cancer Center network will be a great
benefit to the patients, bringing the strength of multiple
institutions to bear on specific problems. “There are so many
ways that this can help us to provide better care for our
patients,” he said. ”Sharing technology and data, having
system-wide consultation and joint services like genetic
counseling available, and combining facilities to participate
in national multicenter clinical trials—we will be working
together, not competing with each other.”
New Clinical Trials at Baylor Charles A.
Sammons Cancer Center at Dallas
Site
Location
Number
Principal investigator
Title
Breast
TOPA-D
T01116
Osborne, Cynthia, MD
A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-
0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in
Patients Resistant to Aromatase Inhibitor Therapy
GI /Lung
TOPA - D
11196
McCollum, Andrew, MD
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of
Patients With Advanced NET of GI or Lung Origin
GU
TOPA - D
T01119
Hutson, Thomas, DO
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Hematology
Baylor
012-023
Cooper, Barry, MD
Dallas
A phase 3 open label randomized study to compare the efficacy and safety of Rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma
Baylor
012-054
Levy, Moshe, MD
Dallas
Randomized Phase II Trial of Timed
Sequential Therapy (TST) With Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. “7+3” for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous
Leukemia (AML)
Cancer research studies on the Baylor Dallas campus are conducted through Baylor Research Institute, Texas Oncology, and US Oncology.
Each reviews, approves, and conducts clinical trials independently.
Site
Location
Number
Title
Hematology
Baylor
012-055
Berryman, Brian, MD
Dallas
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination With Rituximab Compared to
Defined Investigator’s Choice Therapy in
Subjects With Relapsed or Refractory CD22-
Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates for Intensive High-
Dose Chemotherapy (B1931008)
Baylor
012-058
Fay, Joseph W., MD
Dallas
A Phase 2, Randomized Study of Bortezomib/ Dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma
Baylor
012-128
Fay, Joseph W., MD
Dallas
A Phase 1 Study of ARRY-520 and Bortezomib
Plus Dexamethasone in Patients with
Relapsed/Refractory Multiple Myeloma
Neuro
Baylor
011-263
Fink, Karen, MD, PhD
Dallas
An International Renadomized, Double Blind, Controlled Study of Rindopepimut/GM-GCSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-Positive Glioblastoma
Baylor
012-027
Dallas
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent
Glioblastoma
Physicians and their patients can now access information about open clinical trials in oncology at Baylor Sammons Cancer
Center by following these steps:
• Go to BaylorHealth.edu/Sammons.
• Click on “Cancer Clinical Trials” on the right-hand menu.
• From the list of studies that appears, click on the study that is of interest to you to view details such as the inclusion/
exclusion criteria.
For additional details or questions about the studies, please contact the Office of Clinical Oncology Research Coordination
at 214.818.8472 or via e-mail at [email protected].
Site
Location
Number
Title
Neuro
Baylor
012-092
Dallas
A Randomized, Double-Blind, PlaceboControlled, Multicenter Phase II Study
Evaluating the Efficacy and Safety of
Onartuzumab in Combination With
Bevacizumab or ONARTUZUMAB
Monotherapy in Patients with Recurrent
Glioblastoma
Solid Tumor
Cancer Genomic Test in Advanced Sold Tumors
TOPA - D
11076
Becerra, Carlos R., MD
TOPA - D
T01121
Becerra, Carlos R., MD
A Phase I, Open-label, Multi-center,
Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Upcoming Oncology Meetings
November 2012
15 Society for Neuro-Oncology
Meeting
November 15–18, 2012
Washington, DC
www.soc-neuro-onc.org/
December 2012
4 San Antonio Breast Cancer
Symposium
December 4–8, 2012
San Antonio, Texas
http://www.sabcs.org/
28 Society for Urologic Oncology
Meeting
November 28–30, 2012
Bethesda, MD
http://suonet.org/meetings/default.aspx
8 American Society of Hematology
Annual Meeting
December 8–11, 2012
Atlanta, GA
http://www.hematology.org/meetings/
annual-meeting/
30 ASCO Inaugural Quality Care
Symposium
November 30–December 1, 2012
San Diego, CA
http://quality.asco.org/
January 2013
22 Texas Cancer Vaccine
Symposium
January 22, 2013
Baylor Sammons Cancer Center
Dallas, TX
To register or submit an abstract for a
poster, contact Margaret Hinshelwood
at [email protected]
24 ASCO GI Cancers Symposium
January 24–26, 2013
San Francisco, CA
www.gicasym.org/
Site-Specific Tumor Conferences at Baylor
Charles A. Sammons Cancer Center at Dallas
At Baylor Sammons Cancer Center, a key element at the
heart of our approach to patient care and education is
the site-specific tumor conference program. Rather than
focusing solely on recommendations for patient care, the
site-specific conferences also aim at educating the medical professionals attending the conference. Unlike tumor
boards, continuing medical education credit is available for
physicians who attend. Because several patients with the
same diagnosis are presented at each conference, attendees are provided with an in-depth view from specialists,
accompanied by lively discussion.
Most of the site-specific tumor conferences have been
relocated to the 10th floor conference center in the new
outpatient cancer center. The gynecology and skull base
conferences currently remain at their former locations.
For more information about site-specific tumor
conferences at Baylor Charles A. Sammons Cancer
Center, please call 214.820.4073.
Conference Schedule:
Bone and Soft Tissue
1st Tuesday
Breast
Thursdays
Chest
1st, 2nd and 4th Wednesday
Endocrine
3rd Tuesday
Genetics Journal Club/
Case Conference
Mondays
GI
Alternating Thursdays
Gynecology
Wednesdays
Head and Neck
2nd and 4th Tuesday
Head and Neck
Journal Club
5th Tuesdays
Hematology/Oncology
Journal Club*
Rotating Wednesdays
Hematology*
Rotating Wednesdays
Liver
2nd Tuesday
Lymphoma*
Rotating Wednesdays
Neuro-oncology
2nd and 4th Wednesday
Pancreas
1st and 3rd Friday
Skin
1st and 3rd Wednesday
Skull Base
1st Wednesday
Stem Cell Transplant*
Rotating Wednesdays
Urology
3rd Wednesday
*Rotate during the month
Recent Publications from Baylor Sammons Cancer Center
April 1, 2012 to August 20, 2012
1. Banchereau J, Thompson-Snipes L,
Zurawski S, Blanck JP, Cao Y, Clayton
S, Gorvel JP, Zurawski G, Klechevsky E.
The differential production of cytokines
by human Langerhans cells and dermal
CD14+ DCs controls CTL priming.
Blood. 2012 Jun 14;119(24):5742-9.
2. Blackwell KL, Burstein HJ, Storniolo AM,
Rugo HS, Sledge G, Aktan G, Ellis C,
Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J. Overall Survival
Benefit With Lapatinib in Combination
With Trastuzumab for Patients With
Human Epidermal Growth Factor
Receptor 2-Positive Metastatic
Breast Cancer: Final Results From the
EGF104900 Study. J Clin Oncol. 2012
Jul 20;30(21):2585-92.
3. Boland CR. Lynch syndrome: new tales
from the crypt. Lancet Oncol. 2012;13
(6):562-4.
4. Brim H, Lee E, Abu-Asab MS, Chaouchi
M, Razjouyan H, Namin H, Goel A,
Schäffer AA, Ashktorab H. Genomic
Aberrations in an African American
Colorectal Cancer Cohort Reveals a
MSI-Specific Profile and Chromosome
X Amplification in Male Patients. PLoS
One. 2012;7(8):e40392. Epub 2012
Aug 6.
5. Cho DC, Hutson TE, Samlowski W,
Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD,
Flaherty KT, Figlin RA, Vogelzang NJ.
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced
renal cell carcinoma after progression
on vascular endothelial growth factortargeted therapy. Cancer. 2012 Jun 6.
[Epub ahead of print]
6. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Shimon-Paluch S,
Kaufman B, Liljegren A, Lindblom A,
Olsson H, Kristoffersson U, Stenmark
Askmalm M, Melin B, Domchek SM,
Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda
K, Gronwald J, Huzarski T, Cybulski
C, Byrski T, Osorio A, Ramony Cajal T,
Stavropoulou AV, Benítez J, Hamann
U, Rookus MA, Aalfs CM, de Lange J,
Meijers-Heijboer HE, Oosterwijk JC, van
Asperen CJ, Gomez-Garcia EB, Hoogerbrugge N, Jager A, van der Luijt RB,
Easton DF, Peock S, Frost D, Ellis SD,
Platte R, Fineberg E, Evans DG, Lalloo
F, Izatt L, Eeles RA, Adlard J, Davidson
R, Eccles DM, Cole T, Cook J, Brewer
C, Tischkowitz M, Godwin AK, Pathak
HB, Stoppa-Lyonnet D, Sinilnikova
OM, Mazoyer S, Barjhoux L, Leone M,
Gauthier-Villars M, Caux-Moncoutier
V, de Pauw A, Hardouin A, Berthet P,
Dreyfus H, Fert Ferrer S, Collonge-Rame
MA, Sokolowska J, Buys SS, Daly MB,
Miron A, Terry MB, Chung WK, John EM,
Southey MC, Goldgar DE, Singer CF,
Tea Maria MK, Gschwantler-Kaulich D,
Fink-Retter A, Hansen TV, Ejlertsen B,
Johannsson OT, Offit K, Sarrel K, Gaudet
MM, Vijai J, Robson ME, Piedmonte
M, Andrews L, Cohn DE, Demars LR,
Disilvestro P, Rodriguez GC, Toland AE,
Montagna M, Agata S, Imyanitov EN,
Isaacs C, Janavicius R, Lazaro C, Blanco
I, Ramus SJ, Sucheston LE, Karlan BY,
Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S,
Gadzicki D, Varon-Mateeva R, Deissler H,
Gehrig A, Sutter C, Kast K, Nevanlinna H,
Aittomäki K, Simard J, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel JN,
Garber JE, Olopade FI, Rubinstein WS,
Tung N, Blum JL, Narod SA, Brummel
S, Gillen DL, Lindor NM, Fredericksen
Z, Pankratz VS, Couch FJ, Radice P,
Peterlongo P, Greene MH, Loud JT, Mai
PL, Andrulis IL, Glendon G, Ozcelik H,
Gerdes AM, Thomassen M, Jensen UB,
Skytte AB, Caligo MA, Lee A, ChenevixTrench G, Antoniou AC, Neuhausen SL.
A non-synonymous polymorphism in
IRS1 modifies risk of developing breast
and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Cancer Epidemiol Biomarkers Prev. 2012
Jun 26. [Epub ahead of print]
7. Freytes CO, Zhang MJ, Carreras J, Burns
LJ, Gale RP, Isola L, Perales MA, Seftel
M, Vose JM, Miller AM, Gibson J, Gross
TG, Rowlings PA, Inwards DJ, Pavlovsky
S, Martino R, Marks DI, Hale GA, Smith
SM, Schouten HC, Slavin S, Klumpp
TR, Lazarus HM, van Besien K, Hari PN.
Outcome of lower-intensity allogeneic
transplantation in non-hodgkin lymphoma after autologous transplantation
failure. Biol Blood Marrow Transplant.
2012 Aug; 18(8):1255-64.
8. Gopal AK, Ramchandren R, O’Connor
OA, Berryman RB, Advani RH, Chen R,
Smith SE, Cooper M, Rothe A, Matous
JV, Grove LE, Zain J. Safety and efficacy
of brentuximab vedotin for Hodgkin
lymphoma recurring after allogeneic
stem cell transplantation. Blood. 2012
Jul 19;120(3):560-8.
9. Hur K, Han TS, Jung EJ, Yu J, Lee HJ,
Kim WH, Goel A, Yang HK. Up-regulated
expression of sulfatases (SULF1 and
SULF2) as prognostic and metastasis
predictive markers in human gastric
cancer. J Pathol. 2012 May 31. [Epub
ahead of print]
10.Hur K, Toiyama Y, Takahashi M, Balaguer
F, Nagasaka T, Koike J, Hemmi H, Koi
M, Boland CR, Goel A. MicroRNA-200c
modulates epithelial-to-mesenchymal
transition (EMT) in human colorectal cancer metastasis. Gut. 2012 Jul 10. [Epub
ahead of print]
11.Infante JR, Fecher LA, Falchook GS,
Nallapareddy S, Gordon MS, Becerra
C, Demarini DJ, Cox DS, Xu Y, Morris
SR, Peddareddigari VG, Le NT, Hart L,
Bendell JC, Eckhardt G, Kurzrock R,
Flaherty K, Burris HA 3rd, Messersmith
WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the
oral MEK inhibitor trametinib: a phase 1
dose-escalation trial. Lancet Oncol. 2012
Aug;13(8):773-81.
12.Jennings AW, Preskitt JT, Vallera RD.
Extraadrenal pheochromocytoma and
vagal paraganglioma. Proc (Bayl Univ
Med Cent). 2012 Apr;25(2):152-4.
13.Jones G, Arthurs B, Kaya H, Macdonald
K, Qin R, Fairbanks RK, Lamoreaux WT,
Jawed I, Tward JD, Martincic D, Shivnani
AT, Lee CM. Overall Survival Analysis of
Adjuvant Radiation Versus Observation
in Stage I Testicular Seminoma: A Surveillance, Epidemiology, and End Results
(SEER) Analysis. Am J Clin Oncol. 2012
Jul 9. [Epub ahead of print]
14.Kathiria AS, Neumann WL, Rhees J,
Hotchkiss E, Cheng Y, Genta RM, Meltzer SJ, Souza RF, Theiss AL. Prohibitin
attenuates colitis-associated tumorigenesis in mice by modulating p53 and
STAT3 apoptotic responses. Cancer Res.
2012 Aug 6. [Epub ahead of print]
15.Khandani AH, Cowey CL, Moore DT,
Gohil H, Rathmell WK. Primary renal cell
carcinoma: relationship between 18FFDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun. 2012
Sep;33(9):967-73.
16.Kotsopoulos J, Lubinski J, Lynch HT,
Kim-Sing C, Neuhausen S, Demsky
R, Foulkes WD, Ghadirian P, Tung N,
Ainsworth P, Senter L, Karlan B, Eisen A,
Eng C, Weitzel J, Gilchrist DM, Blum JL,
Zakalik D, Singer C, Fallen T, Ginsburg
O, Huzarski T, Sun P, Narod SA. Oophorectomy after Menopause and the Risk
of Breast Cancer in BRCA1 and BRCA2
Mutation Carriers. Cancer Epidemiol
Biomarkers Prev. 2012 Jul;21(7):1089-96.
17.Lin TL, Levy MY. Acute myeloid
leukemia: focus on novel therapeutic
strategies. Clin Med Insights Oncol.
2012;6:205-17.
18.Link A, Becker V, Goel A, Wex T, Malfertheiner P. Feasibility of Fecal MicroRNAs
as Novel Biomarkers for Pancreatic
Cancer. PLoS One. 2012;7(8):e42933.
Epub 2012 Aug 8.
19.Mann S, Patel P, Matthews CM, Pinto
K, O’Connor J. Malignant transformation of endometriosis within the urinary
bladder. Proc (Bayl Univ Med Cent). 2012
Jul;25(3):293-5.
20.Martins FC, De S, Almendro V, Gönen M,
Park SY, Blum JL, Herlihy W, Ethington
G, Schnitt SJ, Tung N, Garber JE, Fetten
K, Michor F, Polyak K. Evolutionary
Pathways in BRCA1-Associated Breast
Tumors. Cancer Discov. 2012; 2(6):503511.
21.Patil S, Figlin RA, Hutson TE, Michaelson
MD, Negrier S, Kim ST, Huang X, Motzer
RJ. Q-TWiST analysis to estimate overall
benefit for patients with metastatic renal
cell carcinoma treated in a phase III trial
of sunitinib vs interferon-α Br J Cancer.
2012 May 8;106(10):1587-90.
22.Powles T, Hutson TE. Difficulty in
predicting survival in metastatic renal
cancer. Lancet Oncol. 2012 Aug 6. [Epub
ahead of print].
23.Santarpia L, Qi Y, Stemke-Hale K, Wang
B, Young EJ, Booser DJ, Holmes FA,
O’Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V,
Hortobagyi GN, Symmans WF, Bottai G,
Di Leo A, Gonzalez-Angulo AM, Pusztai
L. Mutation profiling identifies numerous
rare drug targets and distinct mutation
patterns in different clinical subtypes of
breast cancers. Breast Cancer Res Treat.
2012 Jul;134(1):333-43.
24.Silva EG. The Stromal Origin of Some
Epithelial Ovarian Neoplasms: “Fere
ex nihilo”. Int J Gynecol Cancer. 2012
Jul;22(6):906-7.
25.Smith NZ. Treating metastatic breast
cancer with systemic chemotherapies: current trends and future perspectives. Clin J Oncol Nurs. 2012
Apr;16(2):E33-43.
26.Tran HT, Liu Y, Zurita AJ, Lin Y, BakerNeblett KL, Martin AM, Figlin RA, Hutson
TE, Sternberg CN, Amado RG, Pandite
LN, Heymach JV. Prognostic or predictive
plasma cytokines and angiogenic factors
for patients treated with pazopanib for
metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3
trials. Lancet Oncol. 2012 Jun 29. [Epub
ahead of print]
27.Ubel PA, Berry SR, Nadler E, Bell CM,
Kozminski MA, Palmer JA, Evans WK,
Strevel EL, Neumann PJ. In a survey,
marked inconsistency in how oncologists
judged value of high-cost cancer drugs
in relation to gains in survival. Health Aff
(Millwood). 2012;31(4):709-17.
28.Witta SE, Jotte RM, Konduri K, Neubauer
MA, Spira AI, Ruxer RL, Varella-Garcia
M, Bunn PA Jr, Hirsch FR. Randomized
Phase II Trial of Erlotinib With and Without
Entinostat in Patients With Advanced
Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy. J Clin
Oncol. 2012;30(18):2248-55.
29.Zarghouni M, Vandergriff C, Layton KF,
McGowan JB, Coimbra C, Bhakti A,
Opatowsky MJ. Chordoid glioma of the
third ventricle. Proc (Bayl Univ Med Cent).
2012 Jul;25(3):285-6.
3410 Worth Street
Suite 550
Dallas, Texas 75246
214.820.3535
PRESORTED
FIRST CLASS
US POSTAGE PAID
DALLAS, TX
PERMIT #777
Multiple Myeloma
Research Consortium
Powerful Collaboration Accelerates Results
SAVE
THE
DATE
2 0 1 3
LIVER CANCER–WHAT NOW?
Join us for a continuing education
event to explore the latest in medical
management and surgical advances.
This conference is designed for surgeons,
surgical oncologists, medical oncologists,
radiation oncologists, gastroenterologists,
internal medicine, primary care physicians,
advanced nurse practitioners, and other health
care providers and specialists involved in the
assessment and treatment of GI cancers.
FEBRUARY 9, 2013 • BAYLOR SAMMONS CANCER CENTER
3410 Worth Street • Dallas, Texas 75246
Register Online/More Information: www.camenaegroup.com

Baylor Charles A. Sammons Cancer Center

Transcription

Similar documents

Common Grounds -coffee beanery

KnoWhat2Do brings in Results!

Alpha Kappa Alpha suspension lifted

A Lecture on Liberty

Fall 2 - The Noble NoZe Brotherhood

BU professor honored for outstanding service effort

Spring 1

Down the Years… - Golden Wave Alumni Association, Inc.

Falconry unusual solution to bird problem

No glass left behind: BU to recycle it